Innovent says NMPA grants IBI363 breakthrough therapy status for MSS colorectal cancer
PUBT · 2d ago
Share
Listen to the news
- Innovent received China NMPA CDE Breakthrough Therapy Designation for IBI363 with bevacizumab in advanced MSS/pMMR metastatic colorectal cancer in patients who failed at least two prior treatment lines.
- Phase III trial in China set to start soon for this indication.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605102000PR_NEWS_USPR_____CN55678) on May 11, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending